Cargando…

Protective Effect of Folic Acid on Oxidative DNA Damage: A Randomized, Double-Blind, and Placebo Controlled Clinical Trial

Although previous reports have linked DNA damage with both transmissions across generations as well as our own survival, it is unknown how to reverse the lesion. Based on the data from a Randomized, Double-blind, Placebo Controlled Clinical Trial, this study aimed to assess the efficacy of folic aci...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Xiaojuan, Cui, Huan, Zhang, Haiyang, Guan, Xiaoju, Zhang, Zheng, Jia, Chaonan, Wu, Jia, Yang, Hui, Qiu, Wenting, Zhang, Chuanwu, Yang, Zuopeng, Chen, Zhu, Mao, Guangyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4912249/
https://www.ncbi.nlm.nih.gov/pubmed/26559255
http://dx.doi.org/10.1097/MD.0000000000001872
_version_ 1782438235022032896
author Guo, Xiaojuan
Cui, Huan
Zhang, Haiyang
Guan, Xiaoju
Zhang, Zheng
Jia, Chaonan
Wu, Jia
Yang, Hui
Qiu, Wenting
Zhang, Chuanwu
Yang, Zuopeng
Chen, Zhu
Mao, Guangyun
author_facet Guo, Xiaojuan
Cui, Huan
Zhang, Haiyang
Guan, Xiaoju
Zhang, Zheng
Jia, Chaonan
Wu, Jia
Yang, Hui
Qiu, Wenting
Zhang, Chuanwu
Yang, Zuopeng
Chen, Zhu
Mao, Guangyun
author_sort Guo, Xiaojuan
collection PubMed
description Although previous reports have linked DNA damage with both transmissions across generations as well as our own survival, it is unknown how to reverse the lesion. Based on the data from a Randomized, Double-blind, Placebo Controlled Clinical Trial, this study aimed to assess the efficacy of folic acid supplementation (FAS) on DNA oxidative damage reversal. In this randomized clinical trial (RCT), a total of 450 participants were enrolled and randomly assigned to 3 groups to receive folic acid (FA) 0.4 mg/day (low-FA), 0.8 mg/day (high-FA), or placebo (control) for 8 weeks. The urinary 8-hydroxy-2’-deoxyguanosine (8-OHdG) and creatinine (Cr) concentration at pre- and post-FAS were measured with modified enzyme-linked immunosorbent assay (ELISA) and high-performance liquid chromatography (HPLC), respectively. A multivariate general linear model was applied to assess the individual effects of FAS and the joint effects between FAS and hypercholesterolemia on oxidative DNA damage improvement. This clinical trial was registered with ClinicalTrials.gov, number NCT02235948. Of the 438 subjects that received FA fortification or placebo, the median (first quartile, third quartile) of urinary 8-OHdG/Cr for placebo, low-FA, and high-FA groups were 58.19 (43.90, 82.26), 53.51 (38.97, 72.74), 54.73 (39.58, 76.63) ng/mg at baseline and 57.77 (44.35, 81.33), 51.73 (38.20, 71.30), and 50.65 (37.64, 76.17) ng/mg at the 56th day, respectively. A significant decrease of urinary 8-OHdG was observed after 56 days FA fortification (P < 0.001). Compared with the placebo, after adjusting for some potential confounding factors, including the baseline urinary 8-OHdG/Cr, the urinary 8-OHdG/Cr concentration significantly decreased after 56 days FAS [β (95% confidence interval) = −0.88 (−1.62, −0.14) and P = 0.020 for low-FA; and β (95% confidence interval) = −2.68 (−3.42, −1.94) and P < 0.001 for high-FA] in a dose-response fashion (P(trend) < 0.001). Test of interaction between hypercholesterolemia and FA supplementation on urinary 8-OHdG reduction was significant (P = 0.001). The present study demonstrates that FA fortification is independently linked to the reduction of urinary 8-OHdG/Cr in a dose-related pattern, which suggests that FA is beneficial to protect against oxidative damage to DNA. This effect is apparently stronger in those with hypercholesterolemia. The authors provide a new insight into the prevention and reversal of oxidative DNA damage.
format Online
Article
Text
id pubmed-4912249
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-49122492016-06-28 Protective Effect of Folic Acid on Oxidative DNA Damage: A Randomized, Double-Blind, and Placebo Controlled Clinical Trial Guo, Xiaojuan Cui, Huan Zhang, Haiyang Guan, Xiaoju Zhang, Zheng Jia, Chaonan Wu, Jia Yang, Hui Qiu, Wenting Zhang, Chuanwu Yang, Zuopeng Chen, Zhu Mao, Guangyun Medicine (Baltimore) 4400 Although previous reports have linked DNA damage with both transmissions across generations as well as our own survival, it is unknown how to reverse the lesion. Based on the data from a Randomized, Double-blind, Placebo Controlled Clinical Trial, this study aimed to assess the efficacy of folic acid supplementation (FAS) on DNA oxidative damage reversal. In this randomized clinical trial (RCT), a total of 450 participants were enrolled and randomly assigned to 3 groups to receive folic acid (FA) 0.4 mg/day (low-FA), 0.8 mg/day (high-FA), or placebo (control) for 8 weeks. The urinary 8-hydroxy-2’-deoxyguanosine (8-OHdG) and creatinine (Cr) concentration at pre- and post-FAS were measured with modified enzyme-linked immunosorbent assay (ELISA) and high-performance liquid chromatography (HPLC), respectively. A multivariate general linear model was applied to assess the individual effects of FAS and the joint effects between FAS and hypercholesterolemia on oxidative DNA damage improvement. This clinical trial was registered with ClinicalTrials.gov, number NCT02235948. Of the 438 subjects that received FA fortification or placebo, the median (first quartile, third quartile) of urinary 8-OHdG/Cr for placebo, low-FA, and high-FA groups were 58.19 (43.90, 82.26), 53.51 (38.97, 72.74), 54.73 (39.58, 76.63) ng/mg at baseline and 57.77 (44.35, 81.33), 51.73 (38.20, 71.30), and 50.65 (37.64, 76.17) ng/mg at the 56th day, respectively. A significant decrease of urinary 8-OHdG was observed after 56 days FA fortification (P < 0.001). Compared with the placebo, after adjusting for some potential confounding factors, including the baseline urinary 8-OHdG/Cr, the urinary 8-OHdG/Cr concentration significantly decreased after 56 days FAS [β (95% confidence interval) = −0.88 (−1.62, −0.14) and P = 0.020 for low-FA; and β (95% confidence interval) = −2.68 (−3.42, −1.94) and P < 0.001 for high-FA] in a dose-response fashion (P(trend) < 0.001). Test of interaction between hypercholesterolemia and FA supplementation on urinary 8-OHdG reduction was significant (P = 0.001). The present study demonstrates that FA fortification is independently linked to the reduction of urinary 8-OHdG/Cr in a dose-related pattern, which suggests that FA is beneficial to protect against oxidative damage to DNA. This effect is apparently stronger in those with hypercholesterolemia. The authors provide a new insight into the prevention and reversal of oxidative DNA damage. Wolters Kluwer Health 2015-11-13 /pmc/articles/PMC4912249/ /pubmed/26559255 http://dx.doi.org/10.1097/MD.0000000000001872 Text en Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
spellingShingle 4400
Guo, Xiaojuan
Cui, Huan
Zhang, Haiyang
Guan, Xiaoju
Zhang, Zheng
Jia, Chaonan
Wu, Jia
Yang, Hui
Qiu, Wenting
Zhang, Chuanwu
Yang, Zuopeng
Chen, Zhu
Mao, Guangyun
Protective Effect of Folic Acid on Oxidative DNA Damage: A Randomized, Double-Blind, and Placebo Controlled Clinical Trial
title Protective Effect of Folic Acid on Oxidative DNA Damage: A Randomized, Double-Blind, and Placebo Controlled Clinical Trial
title_full Protective Effect of Folic Acid on Oxidative DNA Damage: A Randomized, Double-Blind, and Placebo Controlled Clinical Trial
title_fullStr Protective Effect of Folic Acid on Oxidative DNA Damage: A Randomized, Double-Blind, and Placebo Controlled Clinical Trial
title_full_unstemmed Protective Effect of Folic Acid on Oxidative DNA Damage: A Randomized, Double-Blind, and Placebo Controlled Clinical Trial
title_short Protective Effect of Folic Acid on Oxidative DNA Damage: A Randomized, Double-Blind, and Placebo Controlled Clinical Trial
title_sort protective effect of folic acid on oxidative dna damage: a randomized, double-blind, and placebo controlled clinical trial
topic 4400
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4912249/
https://www.ncbi.nlm.nih.gov/pubmed/26559255
http://dx.doi.org/10.1097/MD.0000000000001872
work_keys_str_mv AT guoxiaojuan protectiveeffectoffolicacidonoxidativednadamagearandomizeddoubleblindandplacebocontrolledclinicaltrial
AT cuihuan protectiveeffectoffolicacidonoxidativednadamagearandomizeddoubleblindandplacebocontrolledclinicaltrial
AT zhanghaiyang protectiveeffectoffolicacidonoxidativednadamagearandomizeddoubleblindandplacebocontrolledclinicaltrial
AT guanxiaoju protectiveeffectoffolicacidonoxidativednadamagearandomizeddoubleblindandplacebocontrolledclinicaltrial
AT zhangzheng protectiveeffectoffolicacidonoxidativednadamagearandomizeddoubleblindandplacebocontrolledclinicaltrial
AT jiachaonan protectiveeffectoffolicacidonoxidativednadamagearandomizeddoubleblindandplacebocontrolledclinicaltrial
AT wujia protectiveeffectoffolicacidonoxidativednadamagearandomizeddoubleblindandplacebocontrolledclinicaltrial
AT yanghui protectiveeffectoffolicacidonoxidativednadamagearandomizeddoubleblindandplacebocontrolledclinicaltrial
AT qiuwenting protectiveeffectoffolicacidonoxidativednadamagearandomizeddoubleblindandplacebocontrolledclinicaltrial
AT zhangchuanwu protectiveeffectoffolicacidonoxidativednadamagearandomizeddoubleblindandplacebocontrolledclinicaltrial
AT yangzuopeng protectiveeffectoffolicacidonoxidativednadamagearandomizeddoubleblindandplacebocontrolledclinicaltrial
AT chenzhu protectiveeffectoffolicacidonoxidativednadamagearandomizeddoubleblindandplacebocontrolledclinicaltrial
AT maoguangyun protectiveeffectoffolicacidonoxidativednadamagearandomizeddoubleblindandplacebocontrolledclinicaltrial